

TYME

2019 FACTSHEET

What Drives Us

Today **15 Million** people are living with cancer

by 2026 **20 Million**



Despite medical innovation, patients with advanced cancer need more and better treatment options

Who We Are

TYME is an **emerging biotechnology** company focused on exploring **novel therapeutic approaches** designed to target cancer's unique metabolism.

TYME is advancing proprietary **Cancer Metabolism-Based Therapies (CMBTs™)** for **metastatic cancers**.

TYME To Make An Impact

Our unique science gives us the potential to have a significant influence on the current cancer landscape:

- Offering metastatic cancer patients new treatment options to extend and improve quality of life
- Developing a first-in-class oral CMBT, SM-88, showing compelling initial clinical trial results across 15 cancers
- Advancing our pipeline of CMBTs to change the standard of cancer care

Progress In Our Science Driving Growth

POSITIVE DATA READOUTS

ASCO GI 2019: SM-88 demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients with advanced pancreatic cancer

ASCO GU 2019: SM-88 showed encouraging clinical results without typical hormone-related side effects in Phase II study of patients with biomarker recurrent prostate cancer

ADVANCING CLINICAL DEVELOPMENT WITH ADVOCACY PARTNERS

PanCAN: SM-88 selected as the first experimental arm in the **Precision PromiseSM** pivotal trial platform for pancreatic cancer, designed as a registration-enabling trial with potential for FDA approval

Joseph Ahmed Foundation (JAF): Collaboration with Dr. Sant Chawla and JAF for a Phase II clinical trial in Ewing's and high-risk sarcomas

PUBLICATION

Peer-reviewed publication of SM-88 First Human study in the journal **Investigational New Drugs**

REGULATORY

FDA TYPE C meeting for Pancreatic Pivotal path
Granted pharmaceutical compositions and methods patent


TYMEINC.COM

 twitter.com/tyme_inc

 facebook.com/tymetechnologies

 linkedin.com/company/tymeinc

Investment Highlights



TYMEINC.COM

twitter.com/tyme_inc

facebook.com/tymetechnologies

linkedin.com/company/tymeinc

Our Team

Steve Hoffman

Chairman, Chief Executive Officer

Ben R. Taylor

President, Chief Financial Officer

Michele Korfin

RPh, MBA, Chief Operating Officer

Jonathan Eckard

PhD, Chief Business Officer

Giuseppe Del Priore


MD, MPH, Chief Medical Officer

2019 Value Drivers: Key Moments To Advance Our Science and Impact



A Look Beyond:

Strong pipeline of disease-altering CMBTs focused on high unmet medical needs



*Investigator-initiated trial
GA = gemcitabine/Abraxane®